It’s time to beat cancer

Vigeo is a clinical-stage biopharmaceutical company developing novel therapeutics that can effectively treat multiple types of cancer and improve the lives of patients.

Find Out More

We are building a first-in-class drug discovery pipeline that reprograms the tumor immune microenvironment (TIME). We believe that by reprogramming the TIME, we can significantly improve cancer treatment outcomes.


Vigeo is currently developing therapies that target the TIME by activating thrombospondin-1 (Tsp-1), a naturally occurring potent anti-tumorigenic protein, and one of the body’s own defenses against cancer. Tsp-1 has been shown to attack cancer cells and to prevent their spread through metastasis.

Learn More

OUR <strong>APPROACH</strong>

Our lead

We are currently studying VT1021, a peptide therapeutic agent in a Phase 1 trial.

Working at

Find out more about a career at Vigeo


Latest News

September 26, 2019

Vigeo Therapeutics to Present Results from Its Phase 1 Study Evaluating VT1021 in Patients with Advanced Solid Tumors at the European Society for Medical Oncology (ESMO) 2019 Congress

Read More »

May 31, 2019

Vigeo Therapeutics Presents Preliminary Results from Its Phase 1 Open Label Trial of VT1021 in Patients with Advanced Solid Tumors at ASCO

Read More »